WO2021150638A1 - Compositions and methods for improving visibility of the gastrointestinal tract for endoscopy procedures - Google Patents
Compositions and methods for improving visibility of the gastrointestinal tract for endoscopy procedures Download PDFInfo
- Publication number
- WO2021150638A1 WO2021150638A1 PCT/US2021/014231 US2021014231W WO2021150638A1 WO 2021150638 A1 WO2021150638 A1 WO 2021150638A1 US 2021014231 W US2021014231 W US 2021014231W WO 2021150638 A1 WO2021150638 A1 WO 2021150638A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- user
- total composition
- gastrointestinal tract
- effective amount
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 347
- 238000000034 method Methods 0.000 title claims abstract description 168
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims abstract description 67
- 238000001839 endoscopy Methods 0.000 title claims abstract description 43
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 138
- 239000001243 zingiber officinale rosc. root absolute Substances 0.000 claims abstract description 46
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 28
- 238000011010 flushing procedure Methods 0.000 claims abstract description 15
- 239000011780 sodium chloride Substances 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 27
- 210000002429 large intestine Anatomy 0.000 claims description 26
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 claims description 19
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 claims description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 claims description 18
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 claims description 18
- 238000004140 cleaning Methods 0.000 claims description 11
- 235000010323 ascorbic acid Nutrition 0.000 claims description 9
- 239000011668 ascorbic acid Substances 0.000 claims description 9
- 229960005070 ascorbic acid Drugs 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 6
- 230000000249 desinfective effect Effects 0.000 claims description 6
- 239000004302 potassium sorbate Substances 0.000 claims description 6
- 235000010241 potassium sorbate Nutrition 0.000 claims description 6
- 229940069338 potassium sorbate Drugs 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 229960004106 citric acid Drugs 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 229960002668 sodium chloride Drugs 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 claims description 2
- 230000007661 gastrointestinal function Effects 0.000 abstract description 4
- 238000002052 colonoscopy Methods 0.000 description 45
- 229960004063 propylene glycol Drugs 0.000 description 38
- 235000013772 propylene glycol Nutrition 0.000 description 38
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 32
- 229940083037 simethicone Drugs 0.000 description 32
- 235000006886 Zingiber officinale Nutrition 0.000 description 16
- 235000008397 ginger Nutrition 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- 241000234314 Zingiber Species 0.000 description 15
- 235000002780 gingerol Nutrition 0.000 description 15
- 238000004590 computer program Methods 0.000 description 13
- 210000002249 digestive system Anatomy 0.000 description 12
- 238000010586 diagram Methods 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 210000001072 colon Anatomy 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- -1 polydimethylsiloxanes Polymers 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 230000003116 impacting effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000001841 zingiber officinale Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229940102465 ginger root Drugs 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 206010058667 Oral toxicity Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 2
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- FADFGCOCHHNRHF-VAWYXSNFSA-N [10]-Shogaol Chemical compound CCCCCCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 FADFGCOCHHNRHF-VAWYXSNFSA-N 0.000 description 2
- CZNLTCTYLMYLHL-UHFFFAOYSA-N [6]-Paradol Chemical compound CCCCCCCC(=O)CCC1=CC=C(O)C(OC)=C1 CZNLTCTYLMYLHL-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229940002508 ginger extract Drugs 0.000 description 2
- 235000020708 ginger extract Nutrition 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 231100000418 oral toxicity Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 235000020737 peppermint extract Nutrition 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- KKOXKGNSUHTUBV-UHFFFAOYSA-N racemic zingiberene Natural products CC(C)=CCCC(C)C1CC=C(C)C=C1 KKOXKGNSUHTUBV-UHFFFAOYSA-N 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- KKOXKGNSUHTUBV-LSDHHAIUSA-N zingiberene Chemical compound CC(C)=CCC[C@H](C)[C@H]1CC=C(C)C=C1 KKOXKGNSUHTUBV-LSDHHAIUSA-N 0.000 description 2
- 229930001895 zingiberene Natural products 0.000 description 2
- XZRVRYFILCSYSP-OAHLLOKOSA-N (-)-beta-bisabolene Chemical compound CC(C)=CCCC(=C)[C@H]1CCC(C)=CC1 XZRVRYFILCSYSP-OAHLLOKOSA-N 0.000 description 1
- CXENHBSYCFFKJS-VDQVFBMKSA-N (E,E)-alpha-farnesene Chemical compound CC(C)=CCC\C(C)=C\C\C=C(/C)C=C CXENHBSYCFFKJS-VDQVFBMKSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- GPNSDXAINXYRNZ-UHFFFAOYSA-N 1-dehydrogingerdione Natural products CCCCCC(=CC(=O)C=Cc1ccc(O)c(OC)c1)O GPNSDXAINXYRNZ-UHFFFAOYSA-N 0.000 description 1
- XBGUIVFBMBVUEG-UHFFFAOYSA-N 1-methyl-4-(1,5-dimethyl-4-hexenylidene)-1-cyclohexene Chemical compound CC(C)=CCCC(C)=C1CCC(C)=CC1 XBGUIVFBMBVUEG-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102000047934 Caspase-3/7 Human genes 0.000 description 1
- 108700037887 Caspase-3/7 Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000003908 Cathepsin D Human genes 0.000 description 1
- 108090000258 Cathepsin D Proteins 0.000 description 1
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 1
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 108010068192 Cyclin A Proteins 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 102100025191 Cyclin-A2 Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101100072149 Drosophila melanogaster eIF2alpha gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 1
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000596402 Mus musculus Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 description 1
- 101000800539 Mus musculus Translationally-controlled tumor protein Proteins 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 239000004146 Propane-1,2-diol Substances 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 101000781972 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein wos2 Proteins 0.000 description 1
- 101100234062 Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770) cmk gene Proteins 0.000 description 1
- 102000000763 Survivin Human genes 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 101001009610 Toxoplasma gondii Dense granule protein 5 Proteins 0.000 description 1
- 102100040250 Transcription elongation factor A protein-like 1 Human genes 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- VDFOMVRWDSKWSL-UHFFFAOYSA-N Zerumbone Natural products CC1=C2CC(C)(C)C=C2C(=O)C(=CCC1)C VDFOMVRWDSKWSL-UHFFFAOYSA-N 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- YHBUQBJHSRGZNF-HNNXBMFYSA-N alpha-bisabolene Natural products CC(C)=CCC=C(C)[C@@H]1CCC(C)=CC1 YHBUQBJHSRGZNF-HNNXBMFYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- XZRVRYFILCSYSP-UHFFFAOYSA-N beta-Bisabolene Natural products CC(C)=CCCC(=C)C1CCC(C)=CC1 XZRVRYFILCSYSP-UHFFFAOYSA-N 0.000 description 1
- PHWISBHSBNDZDX-UHFFFAOYSA-N beta-Sesquiphellandrene Natural products CC(C)=CCCC(C)C1CCC(=C)C=C1 PHWISBHSBNDZDX-UHFFFAOYSA-N 0.000 description 1
- PHWISBHSBNDZDX-LSDHHAIUSA-N beta-sesquiphellandrene Chemical compound CC(C)=CCC[C@H](C)[C@H]1CCC(=C)C=C1 PHWISBHSBNDZDX-LSDHHAIUSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229930003493 bisabolene Natural products 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000006680 metabolic alteration Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- OAHWPNUPCSDOGU-UHFFFAOYSA-N trans-10-shogaol Natural products CCCCCCCCCC=CC(=O)CCc1ccc(O)c(CO)c1 OAHWPNUPCSDOGU-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- GIHNTRQPEMKFKO-SKTNYSRSSA-N zerumbone Chemical compound C\C1=C/CC(C)(C)\C=C\C(=O)\C(C)=C\CC1 GIHNTRQPEMKFKO-SKTNYSRSSA-N 0.000 description 1
- GIHNTRQPEMKFKO-UHFFFAOYSA-N zurembone Natural products CC1=CCC(C)(C)C=CC(=O)C(C)=CCC1 GIHNTRQPEMKFKO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Definitions
- the disclosure relates generally to compositions and methods for reducing the presence of gas bubbles in the digestive system and particularly relates to compositions and methods for reducing the presence of gas bubbles in the gastrointestinal tract during an endoscopy procedure.
- the digestive system includes the gastrointestinal tract and other accessory organs of digestion. Digestion involves the breakdown of food into smaller components until nutrients can be absorbed and assimilated into the body.
- the gastrointestinal tract is an organ system within many animals that takes in food, digests the food to extract and absorb energy and nutrients, and expels the remaining waste.
- the mouth, esophagus, stomach, and intestines are part of the gastrointestinal tract.
- the digestive system includes complicated organs performing complex chemical and biological processes. Because the digestive system is very complex, many individuals suffer ailments of the digestive system that may be chronic or transitory. Common ailments of the digestive system include, for example, gastroesophageal reflux disease, irritable bowel syndrome, gallstones, constipation, stomach pains, excessive gas, cancer, tissue abnormalities such as polyps, and others. In some instances, the most effective means for examining the gastrointestinal tract includes viewing the interior of the large intestine by way of a colonoscopy. A colonoscopy is an imaging procedure that involves inserting a specialized endoscope (referred to as a colonoscope) into a patient to view the interior space of the large intestine.
- a colonoscope specialized endoscope
- simethicone is not water soluble and is therefore very difficult to clean off the colonoscope.
- Simethicone can harbor bacteria and biofilm.
- the use of simethicone during colonoscopy procedures can lead to the transmission of disease from patient-to-patient and is therefore not recommended. Therefore, there is a need for improved means for reducing the presence of gas bubbles during colonoscopy procedures without negatively impacting the ability to clean and repurpose the colonoscope after the procedure.
- compositions and methods for reducing the presence of gas bubbles in the gastrointestinal tract during an endoscopy procedure without negatively impact the ability to clean and repurpose the endoscopic equipment are disclosed herein.
- FIG. 1 illustrates the chemical formula of 6-gingerol
- FIG. 2 illustrates the chemical formula of 6-shogael
- FIG. 3 illustrates the chemical formula of propylene glycol
- FIG. 4 illustrates the chemical formula of simethicone
- FIG. 5 is a schematic flow chart diagram of a method for reducing or eliminating gas bubbles in a gastrointestinal tract during an endoscopy procedure
- FIG. 6 is a schematic flow chart diagram of a method for reducing or eliminating gas bubbles in a gastrointestinal tract and for processing a colonoscope following a colonoscopy procedure;
- FIG. 7 is a schematic flow chart diagram of a method for reducing or eliminating gas bubbles in a gastrointestinal tract and for processing a colonoscope following a colonoscopy procedure;
- FIG. 8 is a schematic flow chart diagram of a method for reducing or eliminating gas bubbles in a gastrointestinal tract.
- FIG. 9 is a schematic flow chart diagram of a method for reducing or eliminating gas in a gastrointestinal tract.
- the digestive system is an important component of the body.
- the digestive system includes the gastrointestinal (GI) tract whereby food is digested by the body.
- GI gastrointestinal
- the gastrointestinal tract begins with the mouth and includes the esophagus, stomach, small intestine, large intestine, rectum, and anus.
- the human gastrointestinal tract is a single tube which is approximately nine meters long in relaxed condition. A disorder in any portion of the gastrointestinal tract can result in various malfunctions such as diseases of the digestive system and cancer.
- a colonoscopy is an exam for detecting changes or abnormalities in the gastrointestinal tract.
- a colonoscopy a specialized endoscope referred to as a colonoscope is inserted into the large intestine of the patient.
- the colonoscope includes a long, flexible tube that may be inserted into the patient by way of the rectum.
- the colonoscope includes a small video camera at the distal end of the device that allows a practitioner or computer program to view the interior of the colon. Tissue samples for biopsies may also be taken during the colonoscopy. If necessary, polyps or other types of abnormal tissue can be removed with the colonoscope during the colonoscopy.
- the efficacy of a colonoscopy is highly dependent on preparation of the large intestine.
- Preparation for a colonoscopy may include the administration of substances for reducing the presence of gas bubbles within the large intestine.
- gas bubbles it is common for gas bubbles to still be present in the large intestine during the colonoscopy procedure. In such instances, it is beneficial to flush the large intestine with compositions capable of reducing or eliminating the presence of gas bubbles.
- simethicone is not water soluble and can harbor harmful bacteria and viruses. Simethicone can form a film on the colonoscope that is very challenging to remove prior to the colonoscope being cleaned and disinfected for reuse. Because the simethicone is difficult to remove, the simethicone can cause harmful bacteria and viruses to remain on the colonoscope and then be transmitted to a subsequent patient even after the colonoscope has been disinfected for reuse. If the colonoscope is not fully disinfected, a disease present in the colon of a first patient can be transmitted to one or more subsequent patients because the disease will adhere to the colonoscope during the colonoscopy for the first patient.
- Simethicone is an anti-foaming agent that is used to reduce bloating, discomfort, or pain caused by gas.
- the colon can be flushed with simethicone and sodium phosphate during a colonoscopy to improve visibility of the colon by diminishing air bubbles.
- simethicone is a mixture of polydimethylsiloxanes that work by reducing the surface tension of air bubbles and causing the coalescence of small bubbles into larger ones that can pass more easily. While simethicone is shown to be effective for improving visibility during a colonoscopy, the use of simethicone during a colonoscopy is undesirable and potentially unsafe.
- Simethicone is not water soluble and therefore adheres to the colonoscope and can trap diseases that are present in a patient’s colon.
- the colonoscope is then difficult to clean and can harbor dangerous bacteria and viruses that can be transmitted to subsequent patients despite the performance of standard cleaning and disinfection procedures. Therefore, there is a desire to improve colonoscopy visibility by reducing gas bubbles without negatively impacting the ability to clean and disinfect the colonoscope after use.
- compositions and methods for reducing gas bubbles during a colonoscopy without negatively impacting the ability to disinfect the colonoscope after use includes ginger root extract and propylene glycol.
- the composition is effective for reducing gas bubbles present in the gastrointestinal tract.
- the composition may be ingested by a patient prior to a colonoscopy to reduce the presence of gas bubbles in the patient’s large intestine and therefore prepare the patient for a colonoscopy. Additionally, the composition may flow through the colonoscope to flush the patient’s colon during the colonoscopy.
- compositions and methods for improving gastrointestinal function and reducing symptoms of gas in the gastrointestinal tract include compositions and methods for improving gastrointestinal function and reducing symptoms of gas in the gastrointestinal tract.
- the compositions and methods disclosed herein are water soluble to increase absorption of the active ingredients and improve the efficacy of the active ingredients.
- a composition includes ginger root extract and specifically includes 6-gingerol and 6-shogaol.
- the composition includes an effective amount of ginger root extract for reducing gas in the gastrointestinal tract and improving gastrointestinal function.
- Ginger Zingiber officinale
- the major components in ginger rhizomes are carbohydrates (50-70%), lipids (3-8%), terpenes, and phenolic compounds.
- Terpene components of ginger include zingiberene, ⁇ -bisabolene, a-farnesene, ⁇ -sesquiphellandrene, and a-curcumene.
- Phenolic compounds include gingerol, paradols, and shogaol. Gingerol and shogaol are found in higher quantities than other components of ginger. Ginger further includes amino acids, raw fiber, ash, protein, phytosterols, vitamins, and minerals.
- the aromatic constituents of ginger include zingiberene and bisabolene.
- the pungent constituents include the gingerol-related compounds and the shogaol-related compounds.
- the gingerol- and shogaol-related compounds within ginger rhizome include 6-paradol, 1 -dehydrogingerdione, and 6-diary lhgeptanoids.
- Ginger and its components have been shown to modulate a wide range of signaling molecules.
- Ginger may upregulate or downregulate the gene expression of multiple different genes depending on the target and cellular context.
- Ginger extract increases production of antioxidant enzymes including reduced glutathione (GSH), superoxide dismutase (SOD), and glutathione peroxidase.
- GSH reduced glutathione
- SOD superoxide dismutase
- Ginger additionally targets phase ⁇ detoxification enzymes as well as nuclear localization of the Nrf2 pathway.
- ginger extract inhibits transcription factor NF-kB, inflammatory cytokine, TNF-a, and other enzymes and proteins, which include xanthine oxidase and myeloperoxidase.
- the active ingredients of ginger target several cellular molecules that contribute to cell survival, cell proliferation, and angiogenesis.
- 6-gingerol modulates NF-KB, STAT3, Rb, MAPK, PI3K, Akt, ERK, cIAP1, cyclin A, Cdk, cathepsin D, and caspase-3/7.
- 6-shogaol targets NF- ⁇ B, STAT3, MAPK, PI3k/Akt Ca 2+ signals, COX-2, cyclin D1, survivin, cIAP-1, XIAP, Bcl-2, MMP- 9, caspase activation, ER stress, and eIF2 ⁇ .
- ginger component zerumbone modulates NF-KB, p53
- an effective amount means an amount of an ingredient or a component of the product that is nontoxic, but sufficient to provide the desired effect and performance at a reasonable benefit/risk ratio attending any dietary supplement or product.
- an effective amount of a vitamin or mineral is an amount sufficient to prevent a deficiency thereof and to reduce the incidence of some adverse effects.
- FIG. 1 illustrates the chemical formula of 6-gingerol, which is a form of gingerol.
- Gingerols are chemical compounds found in ginger root extract. Gingerols exhibit antioxidant, antitumor, and anti-inflammatory properties. Ginger root ex extract is shown to be effective at reducing or eliminating the presence of gas bubbles in the gastrointestinal tract.
- Gingerols exhibit powerful medicinal properties. Specifically, gingerols reduce symptoms of nausea, including nausea associated with pregnancy or sea sickness. Gingerols may relieve nausea or vomiting induced by drugs such as general anesthesia or chemotherapy. Gingerols are effective against exercise-induced muscle pain and soreness and may reduce the time to recover from exercise-induced pain or injury. Additionally, gingerols exhibit anti-inflammatory effects and can reduce bone degeneration associated with osteoarthritis. Gingerols are associated with lower blood sugars and improving heart disease risk factors. Further, gingerols and other components of ginger root extract are shown to relieve symptoms of chronic indigestion and other ailments associated with the digestive system.
- a composition includes ginger root extract.
- the ginger root extract may include, for example, 6-gingerol and 6-shogaol.
- the ginger root extract is dried ginger root 1:4 extract in 70% organic cane alcohol.
- the ginger root extract is dried ginger root 1:4 extract in 60% organic cane alcohol.
- the ginger root extract is dried ginger root 1:4 extract in 80% organic cane alcohol.
- FIG. 2 illustrates the chemical formula of 6-shogaol, which is a form of shogaol.
- Shogaols are pungent constituents of ginger root extract similar in chemical structure to gingerols as shown in FIG. 1.
- Shogaols as a group include 4-shogaol, 6-shogaol, 10- shogaol, and 12-shogaol, which are all found in ginger.
- Shogaols are artifacts formed during storage or through excess heat and may be created by a dehydration reaction of gingerols.
- FIG. 3 illustrates the chemical formula of propylene glycol.
- the International Union of Pure and Applied Chemistry (IUPAC) name for propylene glycol is propane- 1,2-diol.
- Propylene glycol is an organic compound with the chemical formula CH 3 CH(OH)CH 2 OH. Propylene glycol is a viscous, colorless liquid that includes two alcohol groups. Propylene glycol is miscible with a range of solvents, including water, acetone, and chloroform. In general, propylene glycol is non-irritation, has a low volatility, and a very low toxicity. Propylene glycol is chiral is sometimes referred to as a-propylene glycol to distinguish from the isomer propane- 1,3-diol, known as ⁇ -propylene glycol.
- Propylene glycol is very low, and large quantities are required to cause perceptible health effects in humans.
- Propylene glycol is metabolized in the human body into pyruvic acid as a normal part of the glucose-metabolism process, acetic acid, lactic acid, and propionaldehyde.
- the potential for long-term oral toxicity of propylene glycol is low and the substance is therefore recognized as safe.
- Propylene glycol is essentially non-irritating to human skin and other human tissues.
- Propylene glycol absorbs water and can be used a solvent. Because propylene glycol is water soluble, propylene glycol can be used in conjunction with ginger root extract and other components to reduce gas bubbles during a colonoscopy without negatively impacting the ability to clean and disinfect the colonoscope.
- a composition comprising propylene glycol and ginger root extract is pushed through a colonoscope or another device to flush the colon during a colonoscopy.
- the composition is effective for reducing or eliminating gas bubbles that are naturally present in the gastrointestinal tract, and therefore, the composition is effective for improving visibility during a colonoscopy.
- the composition can easily be washed off the surfaces of the colonoscope after a procedure such that the colonoscope can be properly cleaned and disinfected. This is a significant improvement over the traditional use of simethicone, as discussed above.
- FIG. 4 illustrates the chemical formula of simethicone.
- Simethicone is traditionally used in preparation for and/or during colonoscopy procedures to reduce or eliminate the presence of gas bubbles in the gastrointestinal tract.
- Simethicone is shown to be effective for reducing or eliminating gas bubbles during a colonoscopy to improve visibility of the colon.
- simethicone is not water soluble and negatively impacts the effectiveness of cleaning and disinfecting a colonoscope after use. For this reason, simethicone can be the root cause of the transmission of disease during a colonoscopy and is therefore not safe for use with colonoscopes.
- simethicone is typically diluted in a water container and injected into the patient via the endoscope’s water channel or auxiliary water channel or injected directly through the endoscope’s instrument port with a syringe.
- Simethicone is difficult to remove from endoscopy equipment. Failure to remove simethicone during manual cleaning reduces the efficacy of the cleaning and disinfecting procedures.
- Simethicone is a form of silicone and is insoluble in both water and alcohol.
- solutions containing simethicone typically include sugars, thickeners, and binding agents. These ingredients can potentially support microbial and biofilm growth and are difficult to remove during cleaning and disinfecting procedures. For these reasons, endoscope manufacturers expressly discourage the use of simethicone in connection with endoscopes or colonoscopes.
- compositions and methods for reducing or eliminating gas bubbles in the gastrointestinal tract without negatively impacting the ability to clean and disinfect endoscopy tools may be ingested prior to a colonoscopy to prepare the gastrointestinal tract for the procedure. Additionally, the compositions disclosed herein may be injected into the patient during the colonoscopy procedure.
- compositions may be injected directly via the colonoscope’ s water channel or auxiliary water channel, or directly through the endoscope’s instrument port with a syringe.
- the compositions disclosed herein are water soluble and are therefore more easily absorbed by the body and cleaned off endoscopy instruments.
- FIG. 5 is a schematic diagram of a method 500 for reducing the presence of gas bubbles in a gastrointestinal tract of a user during an endoscopy procedure.
- the method 500 is performed by a medical practitioner or computer program during a colonoscopy procedure.
- the method 500 begins and a medical practitioner or computer program administers at 502 a composition to a user during an endoscopy procedure, wherein the composition is effective for reducing the presence of gas bubbles in a gastrointestinal tract of the user.
- the method 500 is such that the composition includes an effective amount of ginger root extract for reducing the presence of the gas bubbles in the gastrointestinal tract of the user (see 504).
- the method 500 is such that the composition includes propylene glycol
- administering the composition at 502 includes injecting the composition into the patient.
- the composition may be injected through a colonoscope to eliminate bubbles and improve visualization of the gastrointestinal tract. Flushes of the composition may be injected into the patient during an endoscopy procedure such as a colonoscopy.
- the composition is administered at 502 by manually injecting flushes of the composition into the gastrointestinal tract of the user during the endoscopy procedure.
- the composition is administered at 502 by flushing the composition during the endoscopy procedure through the irrigation and/or water channel of an endoscope such as a colonoscope.
- the composition is administered at 502 by flushing the composition during the endoscopy procedure through an auxiliary water channel.
- FIG. 6 is a schematic diagram of a method 600 for reducing the presence of gas bubbles in a gastrointestinal tract of a user during an endoscopy procedure.
- the method 600 is performed by a medical practitioner or computer program during a colonoscopy procedure.
- the method 600 begins and a medical practitioner or computer program causes a composition to be administered to a user during a colonoscopy procedure at 602.
- the composition is effective for reducing the presence of gas bubbles in a gastrointestinal tract of the user.
- the method 600 is such that the composition includes an effective amount of ginger root extract for reducing the presence of the gas bubbles in the gastrointestinal tract of the user (see 604).
- the method 600 is such that the composition include propylene glycol (see 606).
- the method 600 continues and a medical practitioner or computer program visualizes an interior of the gastrointestinal tract of the user with a colonoscope at 608.
- the method 600 continues and a medical practitioner or computer program causes the colonoscope to be processed to remove traces of the composition at 610.
- the composition is water soluble such that the colonoscope can be rinsed or flushed to remove traces of the composition.
- FIG. 7 is a schematic diagram of a method 700 for reducing the presence of gas bubbles in a gastrointestinal tract of a user during an endoscopy procedure.
- the method 700 is performed by a medical practitioner or computer program during a colonoscopy procedure.
- the method 700 begins and a medical practitioner or computer program causes a composition to be administered to a user during a colonoscopy procedure at 702.
- the composition is effective for reducing the presence of gas bubbles in a gastrointestinal tract of the user.
- the method 700 is such that the composition includes an effective amount of ginger root extract for reducing the presence of the gas bubbles in the gastrointestinal tract of the user (see 704).
- the method 700 is such that the composition include propylene glycol and sodium chloride (see 706).
- the method 700 continues and a medical practitioner or computer program visualizes an interior of the gastrointestinal tract of the user with a colonoscope at 708.
- the method 700 continues and a medical practitioner or computer program causes the colonoscope to be processed to remove traces of the composition at 710.
- the composition is water soluble such that the colonoscope can be rinsed or flushed to remove traces of the composition.
- FIG. 8 is a schematic diagram of a method 800 for reducing the presence of gas bubbles in a gastrointestinal tract of a user.
- the method 800 begins and a medical practitioner or computer program administers at 802 a composition to a user, wherein the composition is effective for reducing the presence of gas bubbles in a gastrointestinal tract of the user.
- the method 800 is such that the composition includes an effective amount of ginger root extract for reducing the presence of the gas bubbles in the gastrointestinal tract of the user (see 804).
- the method 800 is such that the composition includes propylene glycol (see 806).
- FIG. 9 is a schematic diagram of a method 900 for reducing the presence of gas bubbles in a gastrointestinal tract of a user.
- the method 900 begins and a medical practitioner or computer program administers at 902 a composition to a user, wherein the composition is effective for reducing the presence of gas bubbles in a gastrointestinal tract of the user.
- the method 900 is such that the composition includes an effective amount of ginger root extract for reducing the presence of the gas bubbles in the gastrointestinal tract of the user (see 904).
- the method 900 is such that the composition includes propylene glycol and sodium chloride (see 906). Examples
- Table 1 shows an example embodiment of the composition. Table 1:
- Table 2 below shows an example embodiment of the composition.
- Table 3 below shows an example embodiment of the composition.
- Table 4 shows an example embodiment of the composition. Table 4:
- Table 5 below shows an example embodiment of the composition.
- Table 6 below shows an example embodiment of the composition.
- a composition may include a combination of all of the following ingredients, or some, but not all, of the following ingredients: a) Propylene glycol; b) Ginger root extract; c) 6-gingerol; d) 6-shogaol; e) Peppermint extract; f) Citric acid; g) Ascorbic acid; h) Sodium chloride; i) Potassium sorbate; and/or j) Water.
- Embodiments of the composition may comprise, for example, concentrations of propylene glycol as follows: a1) from about 10wt% to about 35wt% the total composition a2) from about 10wt% to about 45wt% the total composition a3) from about 10wt% to about 30wt% the total composition a4) from about 10wt% to about 25wt% the total composition a5) from about 10wt% to about 20wt% the total composition a6) from about 10wt% to about 15wt% the total composition a7) from about 15wt% to about 45wt% the total composition a8) from about 20wt% to about 45wt% the total composition a9) from about 25wt% to about 45wt% the total composition a10) from about 30wt% to about 45wt% the total composition a11) from about 35wt% to about 45wt% the total composition a12) from about 40wt% to about 45wt% the total composition a13) from about 40wt
- Embodiments of the composition may comprise, for example, concentrations of ginger root extract as follows: b1) from about 3wt% to about 15wt% the total composition; b2) from about 3wt% to about 14wt% the total composition; b3) from about 3wt% to about 13wt% the total composition; b4) from about 3wt% to about 12wt% the total composition; b5) from about 3wt% to about 1 lwt% the total composition; b6) from about 3wt% to about 10wt% the total composition; b7) from about 3wt% to about 9wt% the total composition; b8) from about 4wt% to about 15wt% the total composition; b9) from about 5wt% to about 15wt% the total composition; b10) from about 6wt% to about 15wt% the total composition; b11) from about 7wt% to about 15wt% the total composition; b12) from about 8wt% to about 15wt% the
- Embodiments of the composition may comprise, for example, concentrations of peppermint extract as follows: e1) from about 3wt% to about 15wt% the total composition; e2) from about 3wt% to about 14wt% the total composition; e3) from about 3wt% to about 13wt% the total composition; e4) from about 3wt% to about 12wt% the total composition; e5) from about 3wt% to about 1 lwt% the total composition; e6) from about 3wt% to about 10wt% the total composition; e7) from about 3wt% to about 9wt% the total composition; e8) from about 4wt% to about 15wt% the total composition; e9) from about 5wt% to about 15wt% the total composition; e10) from about 6wt% to about 15wt% the total composition; e11) from about 7wt% to about 15wt% the total composition; e12) from about 8wt% to about 15wt%
- Embodiments of the composition may comprise, for example, concentrations of citric acid as follows: e1) from about 2wt% to about 20wt% the total composition; e2) from about 2wt% to about 19wt% the total composition; e3) from about 2wt% to about 18wt% the total composition; e4) from about 2wt% to about 17wt% the total composition; e5) from about 2wt% to about 16wt% the total composition; e6) from about 2wt% to about 15wt% the total composition; e7) from about lwt% to about 10wt% the total composition; e8) from about 2wt% to about 10wt% the total composition; e9) from about 3wt% to about 10wt% the total composition; e10) from about 4wt% to about 10wt% the total composition; e11) from about 5wt% to about 10wt% the total composition; e12) from about lwt% to about 9wt% the
- Embodiments of the composition may comprise, for example, concentrations of ascorbic acid as follows: g1) from about 2wt% to about 20wt% the total composition; g2) from about 2wt% to about 19wt% the total composition; g3) from about 2wt% to about 18wt% the total composition; g4) from about 2wt% to about 17wt% the total composition; g5) from about 2wt% to about 16wt% the total composition; g6) from about 2wt% to about 15wt% the total composition; g7) from about lwt% to about 10wt% the total composition; g8) from about 2wt% to about 10wt% the total composition; g9) from about 3wt% to about 10wt% the total composition; g10) from about 4wt% to about 10wt% the total composition; g11) from about 5wt% to about 10wt% the total composition; g12) from about lwt% to about 9wt%
- Embodiments of the disclosure may comprise, for example, concentrations of sodium chloride as follows: h1) from about lwt% to about 30wt% the total composition; h2) from about lwt% to about 40wt% the total composition; h3) from about lwt% to about 25wt% the total composition; h4) from about lwt% to about 23wt% the total composition; h5) from about lwt% to about 20wt% the total composition; h6) from about lwt% to about 18wt% the total composition; h7) from about lwt% to about 15wt% the total composition; h8) from about lwt% to about 13wt% the total composition; h9) from about lwt% to about 10wt% the total composition; h10) from about lwt% to about 8wt% the total composition; h11) from about lwt% to about 5wt% the total composition; h12) from about l
- any of the concentrations for ingredients for a combination of the ingredients (a) thru (i), for example, as listed above, may indicate the concentration for other ingredients listed above.
- Example 1 is a composition.
- the composition includes an effective amount of ginger root extract for reducing gas bubbles in a gastrointestinal tract.
- the composition includes propylene glycol.
- Example 2 is a composition as in Example 1 , further comprising one or more of citric acid or ascorbic acid.
- Example 3 is a composition as in any of Examples 1-2, further comprising one or more of sodium chloride or potassium sorbate.
- Example 4 is a composition as in any of Examples 1-3, wherein the effective amount of the ginger root extract comprises from about 4wt% to about 25wt% the composition.
- Example 5 is a composition as in any of Examples 1-4, wherein the propylene glycol comprises from about 10wt% to about 30wt% the composition.
- Example 6 is a composition as in any of Examples 1-5, further comprising water, wherein the water comprises from about 50wt% to about 85wt% the composition.
- Example 7 is a composition as in any of Examples 1 -6, wherein the composition is prepared for oral administration.
- Example 8 is a composition as in any of Examples 1-7, wherein the composition is prepared for intravenous or intramuscular administration.
- Example 9 is a composition as in any of Examples 1-8, wherein the effective amount of the ginger root extract comprises 6-gingerol and 6-shogaol.
- Example 10 is a composition as in any of Examples 1-9, wherein the composition is water soluble.
- Example 11 is a method.
- the method includes providing a composition to a user for reducing gas bubbles in a gastrointestinal tract of the user.
- the composition includes an effective amount of ginger root extract for reducing the gas bubbles in the gastrointestinal tract of the user.
- the composition includes propylene glycol.
- Example 12 is a method as in Example 11, wherein the composition further comprises one or more of citric acid or ascorbic acid.
- Example 13 is a method as in any of Examples 11-12, wherein the composition further comprises one or more of sodium chloride or potassium sorbate.
- Example 14 is a method as in any of Examples 11-13, wherein the effective amount of the ginger root extract comprises from about 4wt% to about 25wt% the composition.
- Example 15 is a method as in any of Examples 11-14, wherein the propylene glycol comprises from about 10wt% to about 30wt% the composition.
- Example 16 is a method as in any of Examples 11-15, wherein the composition further comprises water, and wherein the water comprises from about 50wt% to about 85wt% the composition.
- Example 17 is a method as in any of Examples 11-16, wherein the composition is prepared for oral administration.
- Example 18 is a method as in any of Examples 11-17, wherein the composition is prepared for intravenous or intramuscular administration.
- Example 19 is a method as in any of Examples 11-18, wherein the effective amount of the ginger root extract comprises 6-gingerol and 6-shogaol.
- Example 20 is a method as in any of Examples 11-19, wherein the composition is water soluble.
- Example 21 is a method. The method includes administering a composition to a user during an endoscopy procedure.
- the composition includes an effective amount of ginger root extract for reducing a presence of gas bubbles in the gastrointestinal tract of the user.
- the composition includes propylene glycol.
- Example 22 is a method as in Example 21, wherein the composition further comprises one or more of citric acid or ascorbic acid.
- Example 23 is a method as in any of Examples 21-22, wherein the composition further comprises one or more of sodium chloride or potassium sorbate.
- Example 24 is a method as in any of Examples 21-23, wherein the effective amount of the ginger root extract comprises from about 4wt% to about 25wt% the composition.
- Example 25 is a method as in any of Examples 21-24, wherein the propylene glycol comprises from about 10wt% to about 30wt% the composition.
- Example 26 is a method as in any of Examples 21-25, wherein the composition further comprises water, and wherein the water comprises from about 50wt% to about 85wt% the composition.
- Example 27 is a method as in any of Examples 21-26, wherein the composition is prepared for oral administration.
- Example 28 is a method as in any of Examples 21-27, wherein the composition is prepared for intravenous or intramuscular administration.
- Example 29 is a method as in any of Examples 21-28, wherein the effective amount of the ginger root extract comprises 6-gingerol and 6-shogaol.
- Example 30 is a method as in any of Examples 21-29, wherein the composition is water soluble.
- Example 31 is a method as in any of Examples 21-30, wherein administering the composition comprises providing the composition to the user for consumption prior to the endoscopy procedure.
- Example 32 is a method as in any of Examples 21-31, wherein administering the composition comprises flushing a large intestine of the user with the composition during the endoscopy procedure.
- Example 33 is a method as in any of Examples 21-32, wherein flushing the large intestine of the user comprises injecting the composition into the large intestine of the user via a water channel and/or auxiliary channel of an endoscopic instrument used for performing the endoscopy procedure.
- Example 34 is a method as in any of Examples 21-33, wherein flushing the large intestine of the user comprises directly injecting the composition into the large intestine of the user with a syringe.
- Example 35 is a method as in any of Examples 21-34, further comprising cleaning an endoscopic device used for performing the endoscopy procedure by washing the endoscopic device with water.
- Example 36 is a method as in any of Examples 21-35, further comprising cleaning an endoscopic device used for performing the endoscopy procedure by washing the endoscopic device with alcohol.
- Example 37 is a method as in any of Examples 21-36, further comprising disinfecting an endoscopic device used for performing the endoscopy procedure such that the endoscopic device can be repurposed.
- Example 38 is a method for increasing visibility of a gastrointestinal tract of a user during an endoscopy procedure.
- the method includes flushing at least a portion of the gastrointestinal tract of the user with a composition during the endoscopy procedure.
- the composition includes an effective amount of ginger root extract for reducing a presence of gas bubbles in the gastrointestinal tract of the user.
- the composition includes propylene glycol.
- the composition includes sodium chloride.
- Example 39 is a method as in Example 38, wherein the composition further comprises one or more of citric acid or ascorbic acid.
- Example 40 is a method as in any of Examples 38-39, wherein the propylene glycol is an effective amount of propylene glycol for making the composition water soluble and increasing absorption by the user of the effective amount of the ginger root extract.
- Example 41 is a method as in any of Examples 38-40, wherein the effective amount of the ginger root extract comprises from about 3wt% to about 25wt% the composition.
- Example 42 is a method as in any of Examples 38-41, wherein the propylene glycol comprises from about 10wt% to about 40wt% the composition.
- Example 43 is a method as in any of Examples 38-42, wherein the composition further comprises water, and wherein the water comprises from about 20wt% to about 85wt% the composition.
- Example 44 is a method as in any of Examples 38-43, further comprising providing the composition to the user for consumption prior to the endoscopy procedure.
- Example 45 is a method as in any of Examples 38-44, wherein flushing at least a portion of the gastrointestinal tract of the user comprises injecting the composition into a large intestine of the user via a water channel and/or auxiliary channel of an endoscopic instrument used for performing the endoscopy procedure.
- Example 46 is a method as in any of Examples 38-45, wherein flushing at least a portion of the gastrointestinal tract of the user comprises directly injecting the composition into a large intestine of the user with a syringe.
- Example 47 is a method as in any of Examples 38-46, wherein the effective amount of the ginger root extract comprises 6-gingerol and 6-shogaol.
- Example 48 is a method as in any of Examples 38-47, wherein the composition is water soluble.
- Example 49 is a method as in any of Examples 38-48, further comprising cleaning an endoscopic device used for performing the endoscopy procedure by washing the endoscopic device with water.
- Example 50 is a method as in any of Examples 38-49, further comprising cleaning an endoscopic device used for performing the endoscopy procedure by washing the endoscopic device with alcohol.
- Example 51 is a method as in any of Examples 38-50, further comprising disinfecting an endoscopic device used for performing the endoscopy procedure such that the endoscopic device can be repurposed.
- Example 42 is a composition.
- the composition includes an effective amount of ginger root extract for reducing a presence of gas bubbles in at least a portion of a gastrointestinal tract of a user.
- the composition includes propylene glycol.
- the composition includes sodium chloride.
- Example 43 is a composition as in Example 42, further comprising one or more of citric acid, ascorbic acid, sodium chloride, or potassium sorbate.
- Example 44 is a composition as in any of Examples 42-43, wherein the effective amount of the ginger root extract comprises from about 3wt% to about 25wt% the composition.
- Example 45 is a composition as in any of Examples 42-44, wherein the propylene glycol comprises from about 10wt% to about 40wt% the composition.
- Example 46 is a composition as in any of Examples 42-45, wherein the composition further comprises water, and wherein the water comprises from about 20wt% to about 85wt% the composition.
- Example 47 is a composition as in any of Examples 42-46, wherein the composition comprises an effective amount of the propylene glycol for making the composition water soluble and increasing absorption by the user of the effective amount of the ginger root extract.
- Example 48 is a composition as in any of Examples 42-47, wherein the composition is an aqueous solution configured to administered to the user during an endoscopy procedure by flushing a large intestine of the user with the composition.
- Example 49 is a composition as in any of Examples 42-48, wherein the effective amount of the ginger root extract comprises 6-gingerol and 6-shogaol.
- Example 50 is a composition as in any of Examples 42-49, wherein the composition is water soluble.
- Example 51 is a composition as in any of Examples 42-50, wherein the composition is prepared for oral administration to the user.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
Compositions and methods for improving gastrointestinal function and reducing the presence of gas bubbles in a gastrointestinal tract. A method for increasing visibility of a gastrointestinal tract of a user during an endoscopy procedure comprises flushing at least a portion of the gastrointestinal tract of the user with a composition during the endoscopy procedure. The composition includes an effective amount of ginger root extract for reducing a presence of gas bubbles in the gastrointestinal tract of the user, propylene glycol, and sodium chloride.
Description
COMPOSITIONS AND METHODS FOR IMPROVING VISIBILITY OF THE GASTROINTESTINAL
TRACT FOR ENDOSCOPY PROCEDURES
TECHNICAL FIELD
[0001] The disclosure relates generally to compositions and methods for reducing the presence of gas bubbles in the digestive system and particularly relates to compositions and methods for reducing the presence of gas bubbles in the gastrointestinal tract during an endoscopy procedure.
BACKGROUND
[0002] The digestive system includes the gastrointestinal tract and other accessory organs of digestion. Digestion involves the breakdown of food into smaller components until nutrients can be absorbed and assimilated into the body. The gastrointestinal tract is an organ system within many animals that takes in food, digests the food to extract and absorb energy and nutrients, and expels the remaining waste. The mouth, esophagus, stomach, and intestines are part of the gastrointestinal tract.
[0003] The digestive system includes complicated organs performing complex chemical and biological processes. Because the digestive system is very complex, many individuals suffer ailments of the digestive system that may be chronic or transitory. Common ailments of the digestive system include, for example, gastroesophageal reflux disease, irritable bowel syndrome, gallstones, constipation, stomach pains, excessive gas, cancer, tissue abnormalities such as polyps, and others. In some instances, the most effective means for examining the gastrointestinal tract includes viewing the interior of the large intestine by way of a colonoscopy. A colonoscopy is an imaging procedure that involves inserting a specialized endoscope (referred to as a colonoscope) into a patient to view the interior space of the large intestine.
[0004] However, the effectiveness of a colonoscopy is highly dependent on the patient’s preparation for the colonoscopy and further on the presence of gas bubbles in the large intestine. The digestive system naturally produces gas, and therefore it is highly likely that a patient will have gas bubbles present in the large intestine during a colonoscopy procedure. The presence of gas bubbles in the large intestine obstructs the view of the walls of the large intestine and thereby negatively impacts visibility during the procedure. In some instances, a medical practitioner will flush the patient’s large intestine with simethicone during the colonoscopy. Simethicone is known to reduce the surface tension of bubbles to reduce and even eliminate the presence of gas bubbles. However, simethicone is not water soluble and is therefore very difficult to clean off the colonoscope. Simethicone can harbor bacteria and biofilm. The use of simethicone during colonoscopy procedures can lead to the transmission of disease from patient-to-patient and is therefore not recommended. Therefore, there is a need for improved means for reducing the presence of gas bubbles during colonoscopy procedures without negatively impacting the ability to clean and repurpose the colonoscope after the procedure.
[0005] In light of the foregoing, disclosed herein are compositions and methods for reducing the presence of gas bubbles in the gastrointestinal tract during an endoscopy procedure without negatively impact the ability to clean and repurpose the endoscopic equipment.
BRIEF DESCRIPTION OF THE DRAWINGS
[0006] Non-limiting and non-exhaustive implementations of the present disclosure are described with reference to the following figures, wherein like reference numerals refer to like parts throughout the various views unless otherwise specified. Advantages of the present disclosure will become better understood with regard to the following description and accompanying drawings where:
[0007] FIG. 1 illustrates the chemical formula of 6-gingerol;
[0008] FIG. 2 illustrates the chemical formula of 6-shogael;
[0009] FIG. 3 illustrates the chemical formula of propylene glycol;
[0010] FIG. 4 illustrates the chemical formula of simethicone;
[0011] FIG. 5 is a schematic flow chart diagram of a method for reducing or eliminating gas bubbles in a gastrointestinal tract during an endoscopy procedure;
[0012] FIG. 6 is a schematic flow chart diagram of a method for reducing or eliminating gas bubbles in a gastrointestinal tract and for processing a colonoscope following a colonoscopy procedure;
[0013] FIG. 7 is a schematic flow chart diagram of a method for reducing or eliminating gas bubbles in a gastrointestinal tract and for processing a colonoscope following a colonoscopy procedure;
[0014] FIG. 8 is a schematic flow chart diagram of a method for reducing or eliminating gas bubbles in a gastrointestinal tract; and
[0015] FIG. 9 is a schematic flow chart diagram of a method for reducing or eliminating gas in a gastrointestinal tract.
DETAILED DESCRIPTION
[0016] Issues associated with the digestive system and the gastrointestinal (GI) tract are commonly treated with synthetic drugs. Synthetic drugs are expensive and cause genetic and metabolic alterations that can be unsafe for some individuals. Therefore, there is a desire to treat gastrointestinal issues with compositions including natural ingredients and medicinal plants.
[0017] The digestive system is an important component of the body. The digestive system includes the gastrointestinal (GI) tract whereby food is digested by the body. The gastrointestinal tract begins with the mouth and includes the esophagus, stomach, small intestine, large intestine, rectum, and anus. The human gastrointestinal tract is a single tube which is approximately nine meters long in relaxed condition. A disorder in any portion of the gastrointestinal tract can result in various malfunctions such as diseases of the digestive system and cancer.
[0018] Some issues associated with the gastrointestinal tract are best examined by way of an endoscopic imaging procedure referred to as a colonoscopy. A colonoscopy is an exam for detecting changes or abnormalities in the gastrointestinal tract. During a colonoscopy, a specialized endoscope referred to as a colonoscope is inserted into the large intestine of the patient. The colonoscope includes a long, flexible tube that may be inserted into the patient by way of the rectum. The colonoscope includes a small video camera at the distal end of the device that allows a practitioner or computer program to view the interior of the colon. Tissue samples for biopsies may also
be taken during the colonoscopy. If necessary, polyps or other types of abnormal tissue can be removed with the colonoscope during the colonoscopy.
[0019] The efficacy of a colonoscopy is highly dependent on preparation of the large intestine. Preparation for a colonoscopy may include the administration of substances for reducing the presence of gas bubbles within the large intestine. However, despite such preparation, it is common for gas bubbles to still be present in the large intestine during the colonoscopy procedure. In such instances, it is beneficial to flush the large intestine with compositions capable of reducing or eliminating the presence of gas bubbles.
[0020] There are some substances known in the art that are effective for reducing the presence of gas bubbles during a colonoscopy procedure. One substance that is commonly used for flushing the large intestine during a colonoscopy is simethicone. However, simethicone is not water soluble and can harbor harmful bacteria and viruses. Simethicone can form a film on the colonoscope that is very challenging to remove prior to the colonoscope being cleaned and disinfected for reuse. Because the simethicone is difficult to remove, the simethicone can cause harmful bacteria and viruses to remain on the colonoscope and then be transmitted to a subsequent patient even after the colonoscope has been disinfected for reuse. If the colonoscope is not fully disinfected, a disease present in the colon of a first patient can be transmitted to one or more subsequent patients because the disease will adhere to the colonoscope during the colonoscopy for the first patient.
[0021] Simethicone is an anti-foaming agent that is used to reduce bloating, discomfort, or pain caused by gas. The colon can be flushed with simethicone and sodium phosphate during a colonoscopy to improve visibility of the colon by diminishing air bubbles. Chemically, simethicone is a mixture of polydimethylsiloxanes that work by reducing the surface tension of air bubbles and causing the coalescence of small bubbles into larger ones that can pass more easily. While simethicone is shown to be effective for improving visibility during a colonoscopy, the use of simethicone during a colonoscopy is undesirable and potentially unsafe. Simethicone is not water soluble and therefore adheres to the colonoscope and can trap diseases that are present in a patient’s colon. When simethicone is used during a colonoscopy, the colonoscope is then difficult to clean and can harbor dangerous bacteria and viruses that can be transmitted to subsequent patients despite the performance of standard cleaning and disinfection procedures. Therefore, there is a desire to improve colonoscopy visibility by reducing gas bubbles without negatively impacting the ability to clean and disinfect the colonoscope after use.
[0022] In light of the foregoing, disclosed herein are compositions and methods for reducing gas bubbles during a colonoscopy without negatively impacting the ability to disinfect the colonoscope after use. In an embodiment, a composition includes ginger root extract and propylene glycol. The composition is effective for reducing gas bubbles present in the gastrointestinal tract. The composition may be ingested by a patient prior to a colonoscopy to reduce the presence of gas bubbles in the patient’s large intestine and therefore prepare the patient for a colonoscopy. Additionally, the composition may flow through the colonoscope to flush the patient’s colon during the colonoscopy.
[0023] Further, embodiments of the disclosure include compositions and methods for improving gastrointestinal function and reducing symptoms of gas in the gastrointestinal tract. The compositions and methods disclosed herein are water soluble to increase absorption of the active ingredients and improve the
efficacy of the active ingredients. In an embodiment, a composition includes ginger root extract and specifically includes 6-gingerol and 6-shogaol. The composition includes an effective amount of ginger root extract for reducing gas in the gastrointestinal tract and improving gastrointestinal function.
[0024] Ginger ( Zingiber officinale) is a member of the Zingiberaceae family. Chemical analysis of ginger shows that it includes over 400 different compounds. The major components in ginger rhizomes are carbohydrates (50-70%), lipids (3-8%), terpenes, and phenolic compounds. Terpene components of ginger include zingiberene, β-bisabolene, a-farnesene, β-sesquiphellandrene, and a-curcumene. Phenolic compounds include gingerol, paradols, and shogaol. Gingerol and shogaol are found in higher quantities than other components of ginger. Ginger further includes amino acids, raw fiber, ash, protein, phytosterols, vitamins, and minerals.
[0025] The aromatic constituents of ginger include zingiberene and bisabolene. The pungent constituents include the gingerol-related compounds and the shogaol-related compounds. The gingerol- and shogaol-related compounds within ginger rhizome include 6-paradol, 1 -dehydrogingerdione, and 6-diary lhgeptanoids.
[0026] Ginger and its components have been shown to modulate a wide range of signaling molecules. Ginger may upregulate or downregulate the gene expression of multiple different genes depending on the target and cellular context. Ginger extract increases production of antioxidant enzymes including reduced glutathione (GSH), superoxide dismutase (SOD), and glutathione peroxidase. Ginger additionally targets phase Π detoxification enzymes as well as nuclear localization of the Nrf2 pathway.
[0027] Additionally, a number of targets of ginger and its components have been documented in different cancer prevention models, including transcription factors, enzymes, inflammatory mediators, protein kinases, drug resistance proteins, adhesion molecules, growth factor receptors, cell-cycle regulatory proteins, cell-survival proteins, chemokines, and chemokine receptors. In different gastrointestinal cancers, ginger extract inhibits transcription factor NF-kB, inflammatory cytokine, TNF-a, and other enzymes and proteins, which include xanthine oxidase and myeloperoxidase.
[0028] The active ingredients of ginger, including 6-gingerol and 6-shogaol, target several cellular molecules that contribute to cell survival, cell proliferation, and angiogenesis. 6-gingerol modulates NF-KB, STAT3, Rb, MAPK, PI3K, Akt, ERK, cIAP1, cyclin A, Cdk, cathepsin D, and caspase-3/7. Similarly, 6-shogaol targets NF-κB, STAT3, MAPK, PI3k/Akt Ca2+ signals, COX-2, cyclin D1, survivin, cIAP-1, XIAP, Bcl-2, MMP- 9, caspase activation, ER stress, and eIF2α. Besides these, ginger component zerumbone modulates NF-KB, p53
VEGF, p21, and CXCR4 expression. [0029] In the following description of the disclosure, reference is made to the accompanying drawings, which form a part hereof, and in which is shown by way of illustration specific implementations in which the disclosure may be practiced. It is understood that other implementations may be utilized, and structural changes may be made without departing from the scope of the disclosure.
[0030] Before the structures, systems, methods, and compositions for improving gastrointestinal function and reducing gas bubbles during a colonoscopy are disclosed and described, it is to be understood that this disclosure is not limited to the particular structures, configurations, process steps, and materials disclosed herein as such structures, configurations, process steps, and materials may vary somewhat. It is also to be understood
that the terminology employed herein is used for the purpose of describing particular embodiments only and is not intended to be limiting since the scope of the disclosure will be limited only by the appended claims and equivalents thereof.
[0031] In describing and claiming the subject matter of the disclosure, the following terminology will be used in accordance with the definitions set out below.
[0032] As used herein, the terms “comprising,” “including,” “containing,” “characterized by,” and grammatical equivalents thereof are inclusive or open-ended terms that do not exclude additional, unrecited elements or method steps.
[0033] As used herein, the phrase “consisting of” and grammatical equivalents thereof exclude any element, step, or ingredient not specified in the claim.
[0034] As used herein, the phrase “consisting essentially of” and grammatical equivalents thereof limit the scope of a claim to the specified ingredients, materials, or steps and those that do not materially affect the basic and novel characteristic or characteristics of the claimed disclosure.
[0035] As used herein, “effective amount” means an amount of an ingredient or a component of the product that is nontoxic, but sufficient to provide the desired effect and performance at a reasonable benefit/risk ratio attending any dietary supplement or product. For example, an effective amount of a vitamin or mineral is an amount sufficient to prevent a deficiency thereof and to reduce the incidence of some adverse effects.
[0036] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this disclosure pertains and belongs.
[0037] Reference will now be made in detail to the exemplary embodiments, examples of which are illustrated in the accompanying drawings. Wherever possible, the same reference numbers are used throughout the drawings to refer to the same or like parts. It is further noted that elements disclosed with respect to particular embodiments are not restricted to only those embodiments in which they are described. For example, an element described in reference to one embodiment or figure, may be alternatively included in another embodiment or figure regardless of whether or not those elements are shown or described in another embodiment or figure. In other words, elements in the figures may be interchangeable between various embodiments disclosed herein, whether shown or not.
[0038] Referring now to the figures, FIG. 1 illustrates the chemical formula of 6-gingerol, which is a form of gingerol. Gingerols are chemical compounds found in ginger root extract. Gingerols exhibit antioxidant, antitumor, and anti-inflammatory properties. Ginger root ex extract is shown to be effective at reducing or eliminating the presence of gas bubbles in the gastrointestinal tract.
[0039] Gingerols exhibit powerful medicinal properties. Specifically, gingerols reduce symptoms of nausea, including nausea associated with pregnancy or sea sickness. Gingerols may relieve nausea or vomiting induced by drugs such as general anesthesia or chemotherapy. Gingerols are effective against exercise-induced muscle pain and soreness and may reduce the time to recover from exercise-induced pain or injury. Additionally, gingerols exhibit anti-inflammatory effects and can reduce bone degeneration associated with osteoarthritis. Gingerols are associated with lower blood sugars and improving heart disease risk factors. Further, gingerols and
other components of ginger root extract are shown to relieve symptoms of chronic indigestion and other ailments associated with the digestive system.
[0040] In an embodiment, a composition includes ginger root extract. The ginger root extract may include, for example, 6-gingerol and 6-shogaol. In an embodiment, the ginger root extract is dried ginger root 1:4 extract in 70% organic cane alcohol. In an embodiment, the ginger root extract is dried ginger root 1:4 extract in 60% organic cane alcohol. In an embodiment, the ginger root extract is dried ginger root 1:4 extract in 80% organic cane alcohol.
[0041] FIG. 2 illustrates the chemical formula of 6-shogaol, which is a form of shogaol. Shogaols are pungent constituents of ginger root extract similar in chemical structure to gingerols as shown in FIG. 1. Shogaols as a group include 4-shogaol, 6-shogaol, 10- shogaol, and 12-shogaol, which are all found in ginger. Shogaols are artifacts formed during storage or through excess heat and may be created by a dehydration reaction of gingerols. [0042] FIG. 3 illustrates the chemical formula of propylene glycol. The International Union of Pure and Applied Chemistry (IUPAC) name for propylene glycol is propane- 1,2-diol. Propylene glycol is an organic compound with the chemical formula CH3CH(OH)CH2OH. Propylene glycol is a viscous, colorless liquid that includes two alcohol groups. Propylene glycol is miscible with a range of solvents, including water, acetone, and chloroform. In general, propylene glycol is non-irritation, has a low volatility, and a very low toxicity. Propylene glycol is chiral is sometimes referred to as a-propylene glycol to distinguish from the isomer propane- 1,3-diol, known as β-propylene glycol.
[0043] The oral toxicity of propylene glycol is very low, and large quantities are required to cause perceptible health effects in humans. Propylene glycol is metabolized in the human body into pyruvic acid as a normal part of the glucose-metabolism process, acetic acid, lactic acid, and propionaldehyde. The potential for long-term oral toxicity of propylene glycol is low and the substance is therefore recognized as safe. Propylene glycol is essentially non-irritating to human skin and other human tissues.
[0044] Propylene glycol absorbs water and can be used a solvent. Because propylene glycol is water soluble, propylene glycol can be used in conjunction with ginger root extract and other components to reduce gas bubbles during a colonoscopy without negatively impacting the ability to clean and disinfect the colonoscope. In an embodiment, a composition comprising propylene glycol and ginger root extract is pushed through a colonoscope or another device to flush the colon during a colonoscopy. The composition is effective for reducing or eliminating gas bubbles that are naturally present in the gastrointestinal tract, and therefore, the composition is effective for improving visibility during a colonoscopy. The composition can easily be washed off the surfaces of the colonoscope after a procedure such that the colonoscope can be properly cleaned and disinfected. This is a significant improvement over the traditional use of simethicone, as discussed above.
[0045] FIG. 4 illustrates the chemical formula of simethicone. Simethicone is traditionally used in preparation for and/or during colonoscopy procedures to reduce or eliminate the presence of gas bubbles in the gastrointestinal tract. Simethicone is shown to be effective for reducing or eliminating gas bubbles during a colonoscopy to improve visibility of the colon. However, simethicone is not water soluble and negatively impacts
the effectiveness of cleaning and disinfecting a colonoscope after use. For this reason, simethicone can be the root cause of the transmission of disease during a colonoscopy and is therefore not safe for use with colonoscopes.
[0046] As discussed above, some gastrointestinal endoscopy practices use simethicone in an effort to improve visualizing during endoscopy. In this case, simethicone is typically diluted in a water container and injected into the patient via the endoscope’s water channel or auxiliary water channel or injected directly through the endoscope’s instrument port with a syringe. Simethicone is difficult to remove from endoscopy equipment. Failure to remove simethicone during manual cleaning reduces the efficacy of the cleaning and disinfecting procedures. Simethicone is a form of silicone and is insoluble in both water and alcohol. In addition, solutions containing simethicone typically include sugars, thickeners, and binding agents. These ingredients can potentially support microbial and biofilm growth and are difficult to remove during cleaning and disinfecting procedures. For these reasons, endoscope manufacturers expressly discourage the use of simethicone in connection with endoscopes or colonoscopes.
[0047] Because simethicone is insoluble in both alcohol and water and is therefore difficult to remove from the surfaces of endoscopes and colonoscopes, there is a need for water soluble compositions that can effectively reduce or eliminate gas bubbles present in the gastrointestinal tract. Disclosed herein are compositions and methods for reducing or eliminating gas bubbles in the gastrointestinal tract without negatively impacting the ability to clean and disinfect endoscopy tools. The compositions disclosed herein may be ingested prior to a colonoscopy to prepare the gastrointestinal tract for the procedure. Additionally, the compositions disclosed herein may be injected into the patient during the colonoscopy procedure. The compositions may be injected directly via the colonoscope’ s water channel or auxiliary water channel, or directly through the endoscope’s instrument port with a syringe. The compositions disclosed herein are water soluble and are therefore more easily absorbed by the body and cleaned off endoscopy instruments.
[0048] FIG. 5 is a schematic diagram of a method 500 for reducing the presence of gas bubbles in a gastrointestinal tract of a user during an endoscopy procedure. In an embodiment, the method 500 is performed by a medical practitioner or computer program during a colonoscopy procedure.
[0049] The method 500 begins and a medical practitioner or computer program administers at 502 a composition to a user during an endoscopy procedure, wherein the composition is effective for reducing the presence of gas bubbles in a gastrointestinal tract of the user. The method 500 is such that the composition includes an effective amount of ginger root extract for reducing the presence of the gas bubbles in the gastrointestinal tract of the user (see 504). The method 500 is such that the composition includes propylene glycol
(see 506). [0050] In an embodiment, administering the composition at 502 includes injecting the composition into the patient. The composition may be injected through a colonoscope to eliminate bubbles and improve visualization of the gastrointestinal tract. Flushes of the composition may be injected into the patient during an endoscopy procedure such as a colonoscopy. In an embodiment, the composition is administered at 502 by manually injecting flushes of the composition into the gastrointestinal tract of the user during the endoscopy procedure. In an embodiment, the composition is administered at 502 by flushing the composition during the endoscopy procedure
through the irrigation and/or water channel of an endoscope such as a colonoscope. In an embodiment, the composition is administered at 502 by flushing the composition during the endoscopy procedure through an auxiliary water channel.
[0051] FIG. 6 is a schematic diagram of a method 600 for reducing the presence of gas bubbles in a gastrointestinal tract of a user during an endoscopy procedure. In an embodiment, the method 600 is performed by a medical practitioner or computer program during a colonoscopy procedure.
[0052] The method 600 begins and a medical practitioner or computer program causes a composition to be administered to a user during a colonoscopy procedure at 602. The composition is effective for reducing the presence of gas bubbles in a gastrointestinal tract of the user. The method 600 is such that the composition includes an effective amount of ginger root extract for reducing the presence of the gas bubbles in the gastrointestinal tract of the user (see 604). The method 600 is such that the composition include propylene glycol (see 606). The method 600 continues and a medical practitioner or computer program visualizes an interior of the gastrointestinal tract of the user with a colonoscope at 608. The method 600 continues and a medical practitioner or computer program causes the colonoscope to be processed to remove traces of the composition at 610. In an embodiment, the composition is water soluble such that the colonoscope can be rinsed or flushed to remove traces of the composition.
[0053] FIG. 7 is a schematic diagram of a method 700 for reducing the presence of gas bubbles in a gastrointestinal tract of a user during an endoscopy procedure. In an embodiment, the method 700 is performed by a medical practitioner or computer program during a colonoscopy procedure.
[0054] The method 700 begins and a medical practitioner or computer program causes a composition to be administered to a user during a colonoscopy procedure at 702. The composition is effective for reducing the presence of gas bubbles in a gastrointestinal tract of the user. The method 700 is such that the composition includes an effective amount of ginger root extract for reducing the presence of the gas bubbles in the gastrointestinal tract of the user (see 704). The method 700 is such that the composition include propylene glycol and sodium chloride (see 706). The method 700 continues and a medical practitioner or computer program visualizes an interior of the gastrointestinal tract of the user with a colonoscope at 708. The method 700 continues and a medical practitioner or computer program causes the colonoscope to be processed to remove traces of the composition at 710. In an embodiment, the composition is water soluble such that the colonoscope can be rinsed or flushed to remove traces of the composition.
[0055] FIG. 8 is a schematic diagram of a method 800 for reducing the presence of gas bubbles in a gastrointestinal tract of a user. The method 800 begins and a medical practitioner or computer program administers at 802 a composition to a user, wherein the composition is effective for reducing the presence of gas bubbles in a gastrointestinal tract of the user. The method 800 is such that the composition includes an effective amount of ginger root extract for reducing the presence of the gas bubbles in the gastrointestinal tract of the user (see 804). The method 800 is such that the composition includes propylene glycol (see 806).
[0056] FIG. 9 is a schematic diagram of a method 900 for reducing the presence of gas bubbles in a gastrointestinal tract of a user. The method 900 begins and a medical practitioner or computer program
administers at 902 a composition to a user, wherein the composition is effective for reducing the presence of gas bubbles in a gastrointestinal tract of the user. The method 900 is such that the composition includes an effective amount of ginger root extract for reducing the presence of the gas bubbles in the gastrointestinal tract of the user (see 904). The method 900 is such that the composition includes propylene glycol and sodium chloride (see 906). Examples
[0057] The following examples pertain to further embodiments. [0058] Table 1 below shows an example embodiment of the composition. Table 1:
[0064] According to one or more embodiments of the disclosure, a composition may include a combination of all of the following ingredients, or some, but not all, of the following ingredients: a) Propylene glycol;
b) Ginger root extract; c) 6-gingerol; d) 6-shogaol; e) Peppermint extract; f) Citric acid; g) Ascorbic acid; h) Sodium chloride; i) Potassium sorbate; and/or j) Water.
[0065] Embodiments of the composition may comprise, for example, concentrations of propylene glycol as follows: a1) from about 10wt% to about 35wt% the total composition a2) from about 10wt% to about 45wt% the total composition a3) from about 10wt% to about 30wt% the total composition a4) from about 10wt% to about 25wt% the total composition a5) from about 10wt% to about 20wt% the total composition a6) from about 10wt% to about 15wt% the total composition a7) from about 15wt% to about 45wt% the total composition a8) from about 20wt% to about 45wt% the total composition a9) from about 25wt% to about 45wt% the total composition a10) from about 30wt% to about 45wt% the total composition a11) from about 35wt% to about 45wt% the total composition a12) from about 40wt% to about 45wt% the total composition a13) from about 40wt% to about 80wt% the total composition a14) from about 30wt% to about 90wt% the total composition a15) from about 20wt% to about 90wt% the total composition a16) from about 45wt% to about 80wt% the total composition a17) from about 50wt% to about 80wt% the total composition a18) from about 60wt% to about 80wt% the total composition a19) from about 60wt% to about 75wt% the total composition a20) from about 60wt% to about 70wt% the total composition a21) from about 60wt% to about 65wt% the total composition a22) from about 50wt% to about 70wt% the total composition a23) from about 52wt% to about 70wt% the total composition a24) from about 54wt% to about 70wt% the total composition a25) from about 56wt% to about 70wt% the total composition a26) from about 58wt% to about 70wt% the total composition
a27) from about 60wt% to about 70wt% the total composition; a28) from about 62wt% to about 70wt% the total composition; a29) from about 64wt% to about 70wt% the total composition; a30) from about 66wt% to about 70wt% the total composition; a31) from about 62wt% to about 67wt% the total composition; a32) from about 63wt% to about 67wt% the total composition; a33) from about 64wt% to about 67wt% the total composition; or a34) from about 64wt% to about 66wt% the total composition.
[0066] Embodiments of the composition may comprise, for example, concentrations of ginger root extract as follows: b1) from about 3wt% to about 15wt% the total composition; b2) from about 3wt% to about 14wt% the total composition; b3) from about 3wt% to about 13wt% the total composition; b4) from about 3wt% to about 12wt% the total composition; b5) from about 3wt% to about 1 lwt% the total composition; b6) from about 3wt% to about 10wt% the total composition; b7) from about 3wt% to about 9wt% the total composition; b8) from about 4wt% to about 15wt% the total composition; b9) from about 5wt% to about 15wt% the total composition; b10) from about 6wt% to about 15wt% the total composition; b11) from about 7wt% to about 15wt% the total composition; b12) from about 8wt% to about 15wt% the total composition; b13) from about 7wt% to about 9wt% the total composition; b14) from about 6wt% to about 10wt% the total composition; b15) from about 6wt% to about 9wt% the total composition; b16) from about 5wt% to about 12wt% the total composition; b17) from about 5wt% to about 10wt% the total composition; b18) from about 2wt% to about 20wt% the total composition; b19) from about 2wt% to about 25wt% the total composition; b20) from about 2wt% to about 30wt% the total composition; b21) from about 2wt% to about 35wt% the total composition; b22) from about 2wt% to about 40wt% the total composition; b23) from about 5wt% to about 40wt% the total composition; b24) from about 5wt% to about 45wt% the total composition; or b25) from about 5wt% to about 50wt% the total composition.
[0067] Embodiments of the composition may comprise, for example, concentrations of peppermint extract as follows:
e1) from about 3wt% to about 15wt% the total composition; e2) from about 3wt% to about 14wt% the total composition; e3) from about 3wt% to about 13wt% the total composition; e4) from about 3wt% to about 12wt% the total composition; e5) from about 3wt% to about 1 lwt% the total composition; e6) from about 3wt% to about 10wt% the total composition; e7) from about 3wt% to about 9wt% the total composition; e8) from about 4wt% to about 15wt% the total composition; e9) from about 5wt% to about 15wt% the total composition; e10) from about 6wt% to about 15wt% the total composition; e11) from about 7wt% to about 15wt% the total composition; e12) from about 8wt% to about 15wt% the total composition; e13) from about 7wt% to about 9wt% the total composition; e14) from about 6wt% to about 10wt% the total composition; e15) from about 6wt% to about 9wt% the total composition; e11) from about 5wt% to about 12wt% the total composition; el7) from about 5wt% to about 10wt% the total composition; e18) from about 2wt% to about 20wt% the total composition; e19) from about 2wt% to about 25wt% the total composition; e20) from about 2wt% to about 30wt% the total composition; e21) from about 2wt% to about 35wt% the total composition; e22) from about 2wt% to about 40wt% the total composition; e23) from about 5wt% to about 40wt% the total composition; e24) from about 5wt% to about 45wt% the total composition; or e25) from about 5wt% to about 50wt% the total composition.
[0068] Embodiments of the composition may comprise, for example, concentrations of citric acid as follows: e1) from about 2wt% to about 20wt% the total composition; e2) from about 2wt% to about 19wt% the total composition; e3) from about 2wt% to about 18wt% the total composition; e4) from about 2wt% to about 17wt% the total composition; e5) from about 2wt% to about 16wt% the total composition; e6) from about 2wt% to about 15wt% the total composition; e7) from about lwt% to about 10wt% the total composition; e8) from about 2wt% to about 10wt% the total composition; e9) from about 3wt% to about 10wt% the total composition; e10) from about 4wt% to about 10wt% the total composition;
e11) from about 5wt% to about 10wt% the total composition; e12) from about lwt% to about 9wt% the total composition; e13) from about lwt% to about 8wt% the total composition; e14) from about lwt% to about 7wt% the total composition; e15) from about lwt% to about 6wt% the total composition; e16) from about 2wt% to about 5wt% the total composition; e17) from about 3wt% to about 5wt% the total composition; e18) from about lwt% to about 15wt% the total composition; e19) from about lwt% to about 20wt% the total composition; e20) from about lwt% to about 25wt% the total composition; e21) from about lwt% to about 30wt% the total composition; or e22) from about lwt% to about 35wt% the total composition.
[0069] Embodiments of the composition may comprise, for example, concentrations of ascorbic acid as follows: g1) from about 2wt% to about 20wt% the total composition; g2) from about 2wt% to about 19wt% the total composition; g3) from about 2wt% to about 18wt% the total composition; g4) from about 2wt% to about 17wt% the total composition; g5) from about 2wt% to about 16wt% the total composition; g6) from about 2wt% to about 15wt% the total composition; g7) from about lwt% to about 10wt% the total composition; g8) from about 2wt% to about 10wt% the total composition; g9) from about 3wt% to about 10wt% the total composition; g10) from about 4wt% to about 10wt% the total composition; g11) from about 5wt% to about 10wt% the total composition; g12) from about lwt% to about 9wt% the total composition; g13) from about lwt% to about 8wt% the total composition; g14) from about lwt% to about 7wt% the total composition; g15) from about lwt% to about 6wt% the total composition; g16) from about 2wt% to about 5wt% the total composition; g17) from about 3wt% to about 5wt% the total composition; g18) from about lwt% to about 15wt% the total composition; g19) from about lwt% to about 20wt% the total composition; g20) from about lwt% to about 25wt% the total composition; g21) from about lwt% to about 30wt% the total composition; or g22) from about lwt% to about 35wt% the total composition.
[0070] Embodiments of the disclosure may comprise, for example, concentrations of sodium chloride as follows: h1) from about lwt% to about 30wt% the total composition; h2) from about lwt% to about 40wt% the total composition; h3) from about lwt% to about 25wt% the total composition; h4) from about lwt% to about 23wt% the total composition; h5) from about lwt% to about 20wt% the total composition; h6) from about lwt% to about 18wt% the total composition; h7) from about lwt% to about 15wt% the total composition; h8) from about lwt% to about 13wt% the total composition; h9) from about lwt% to about 10wt% the total composition; h10) from about lwt% to about 8wt% the total composition; h11) from about lwt% to about 5wt% the total composition; h12) from about lwt% to about 3wt% the total composition; h13) from about lwt% to about 2wt% the total composition; h14) from about 3wt% to about 30wt% the total composition; h15) from about 5wt% to about 30wt% the total composition; h16) from about 8wt% to about 30wt% the total composition; h17) from about 10wt% to about 30wt% the total composition; h18) from about 13wt% to about 30wt% the total composition; h19) from about 15wt% to about 30wt% the total composition; h20) from about 18wt% to about 30wt% the total composition; h21) from about 20wt% to about 30wt% the total composition; h22) from about 25wt% to about 30wt% the total composition;
[0071] The foregoing percentages, concentrations, and ratios are presented by example only and are not intended to be exhaustive or to limit the disclosure to the precise percentages, concentrations, and ratios disclosed. It should be appreciated that each value that falls within a disclosed range is disclosed as if it were individually disclosed as set forth herein. For example, a range indicating a weight percent from about 8% to about 14% additionally includes ranges beginning or ending with all values within that range, including for example a range beginning at 8.1%, 8.2%, 8.3%, 9%, 10%, 11%, 12%, and so forth.
[0072] Also, according to one or more non-limiting embodiments of the disclosure, any of the concentrations for ingredients for a combination of the ingredients (a) thru (i), for example, as listed above, may indicate the concentration for other ingredients listed above.
[0073] Example 1 is a composition. The composition includes an effective amount of ginger root extract for reducing gas bubbles in a gastrointestinal tract. The composition includes propylene glycol.
[0074] Example 2 is a composition as in Example 1 , further comprising one or more of citric acid or ascorbic acid.
[0075] Example 3 is a composition as in any of Examples 1-2, further comprising one or more of sodium chloride or potassium sorbate.
[0076] Example 4 is a composition as in any of Examples 1-3, wherein the effective amount of the ginger root extract comprises from about 4wt% to about 25wt% the composition.
[0077] Example 5 is a composition as in any of Examples 1-4, wherein the propylene glycol comprises from about 10wt% to about 30wt% the composition.
[0078] Example 6 is a composition as in any of Examples 1-5, further comprising water, wherein the water comprises from about 50wt% to about 85wt% the composition.
[0079] Example 7 is a composition as in any of Examples 1 -6, wherein the composition is prepared for oral administration.
[0080] Example 8 is a composition as in any of Examples 1-7, wherein the composition is prepared for intravenous or intramuscular administration.
[0081] Example 9 is a composition as in any of Examples 1-8, wherein the effective amount of the ginger root extract comprises 6-gingerol and 6-shogaol.
[0082] Example 10 is a composition as in any of Examples 1-9, wherein the composition is water soluble.
[0083] Example 11 is a method. The method includes providing a composition to a user for reducing gas bubbles in a gastrointestinal tract of the user. The composition includes an effective amount of ginger root extract for reducing the gas bubbles in the gastrointestinal tract of the user. The composition includes propylene glycol. [0084] Example 12 is a method as in Example 11, wherein the composition further comprises one or more of citric acid or ascorbic acid.
[0085] Example 13 is a method as in any of Examples 11-12, wherein the composition further comprises one or more of sodium chloride or potassium sorbate.
[0086] Example 14 is a method as in any of Examples 11-13, wherein the effective amount of the ginger root extract comprises from about 4wt% to about 25wt% the composition.
[0087] Example 15 is a method as in any of Examples 11-14, wherein the propylene glycol comprises from about 10wt% to about 30wt% the composition.
[0088] Example 16 is a method as in any of Examples 11-15, wherein the composition further comprises water, and wherein the water comprises from about 50wt% to about 85wt% the composition.
[0089] Example 17 is a method as in any of Examples 11-16, wherein the composition is prepared for oral administration.
[0090] Example 18 is a method as in any of Examples 11-17, wherein the composition is prepared for intravenous or intramuscular administration.
[0091] Example 19 is a method as in any of Examples 11-18, wherein the effective amount of the ginger root extract comprises 6-gingerol and 6-shogaol.
[0092] Example 20 is a method as in any of Examples 11-19, wherein the composition is water soluble.
[0093] Example 21 is a method. The method includes administering a composition to a user during an endoscopy procedure. The composition includes an effective amount of ginger root extract for reducing a presence of gas bubbles in the gastrointestinal tract of the user. The composition includes propylene glycol.
[0094] Example 22 is a method as in Example 21, wherein the composition further comprises one or more of citric acid or ascorbic acid.
[0095] Example 23 is a method as in any of Examples 21-22, wherein the composition further comprises one or more of sodium chloride or potassium sorbate.
[0096] Example 24 is a method as in any of Examples 21-23, wherein the effective amount of the ginger root extract comprises from about 4wt% to about 25wt% the composition.
[0097] Example 25 is a method as in any of Examples 21-24, wherein the propylene glycol comprises from about 10wt% to about 30wt% the composition.
[0098] Example 26 is a method as in any of Examples 21-25, wherein the composition further comprises water, and wherein the water comprises from about 50wt% to about 85wt% the composition.
[0099] Example 27 is a method as in any of Examples 21-26, wherein the composition is prepared for oral administration.
[0100] Example 28 is a method as in any of Examples 21-27, wherein the composition is prepared for intravenous or intramuscular administration.
[0101] Example 29 is a method as in any of Examples 21-28, wherein the effective amount of the ginger root extract comprises 6-gingerol and 6-shogaol.
[0102] Example 30 is a method as in any of Examples 21-29, wherein the composition is water soluble.
[0103] Example 31 is a method as in any of Examples 21-30, wherein administering the composition comprises providing the composition to the user for consumption prior to the endoscopy procedure.
[0104] Example 32 is a method as in any of Examples 21-31, wherein administering the composition comprises flushing a large intestine of the user with the composition during the endoscopy procedure.
[0105] Example 33 is a method as in any of Examples 21-32, wherein flushing the large intestine of the user comprises injecting the composition into the large intestine of the user via a water channel and/or auxiliary channel of an endoscopic instrument used for performing the endoscopy procedure.
[0106] Example 34 is a method as in any of Examples 21-33, wherein flushing the large intestine of the user comprises directly injecting the composition into the large intestine of the user with a syringe.
[0107] Example 35 is a method as in any of Examples 21-34, further comprising cleaning an endoscopic device used for performing the endoscopy procedure by washing the endoscopic device with water.
[0108] Example 36 is a method as in any of Examples 21-35, further comprising cleaning an endoscopic device used for performing the endoscopy procedure by washing the endoscopic device with alcohol.
[0109] Example 37 is a method as in any of Examples 21-36, further comprising disinfecting an endoscopic device used for performing the endoscopy procedure such that the endoscopic device can be repurposed.
[0110] Example 38 is a method for increasing visibility of a gastrointestinal tract of a user during an endoscopy procedure. The method includes flushing at least a portion of the gastrointestinal tract of the user with
a composition during the endoscopy procedure. The composition includes an effective amount of ginger root extract for reducing a presence of gas bubbles in the gastrointestinal tract of the user. The composition includes propylene glycol. The composition includes sodium chloride.
[0111] Example 39 is a method as in Example 38, wherein the composition further comprises one or more of citric acid or ascorbic acid.
[0112] Example 40 is a method as in any of Examples 38-39, wherein the propylene glycol is an effective amount of propylene glycol for making the composition water soluble and increasing absorption by the user of the effective amount of the ginger root extract.
[0113] Example 41 is a method as in any of Examples 38-40, wherein the effective amount of the ginger root extract comprises from about 3wt% to about 25wt% the composition.
[0114] Example 42 is a method as in any of Examples 38-41, wherein the propylene glycol comprises from about 10wt% to about 40wt% the composition.
[0115] Example 43 is a method as in any of Examples 38-42, wherein the composition further comprises water, and wherein the water comprises from about 20wt% to about 85wt% the composition.
[0116] Example 44 is a method as in any of Examples 38-43, further comprising providing the composition to the user for consumption prior to the endoscopy procedure.
[0117] Example 45 is a method as in any of Examples 38-44, wherein flushing at least a portion of the gastrointestinal tract of the user comprises injecting the composition into a large intestine of the user via a water channel and/or auxiliary channel of an endoscopic instrument used for performing the endoscopy procedure. [0118] Example 46 is a method as in any of Examples 38-45, wherein flushing at least a portion of the gastrointestinal tract of the user comprises directly injecting the composition into a large intestine of the user with a syringe.
[0119] Example 47 is a method as in any of Examples 38-46, wherein the effective amount of the ginger root extract comprises 6-gingerol and 6-shogaol.
[0120] Example 48 is a method as in any of Examples 38-47, wherein the composition is water soluble.
[0121] Example 49 is a method as in any of Examples 38-48, further comprising cleaning an endoscopic device used for performing the endoscopy procedure by washing the endoscopic device with water.
[0122] Example 50 is a method as in any of Examples 38-49, further comprising cleaning an endoscopic device used for performing the endoscopy procedure by washing the endoscopic device with alcohol.
[0123] Example 51 is a method as in any of Examples 38-50, further comprising disinfecting an endoscopic device used for performing the endoscopy procedure such that the endoscopic device can be repurposed.
[0124] Example 42 is a composition. The composition includes an effective amount of ginger root extract for reducing a presence of gas bubbles in at least a portion of a gastrointestinal tract of a user. The composition includes propylene glycol. The composition includes sodium chloride.
[0125] Example 43 is a composition as in Example 42, further comprising one or more of citric acid, ascorbic acid, sodium chloride, or potassium sorbate.
[0126] Example 44 is a composition as in any of Examples 42-43, wherein the effective amount of the ginger root extract comprises from about 3wt% to about 25wt% the composition.
[0127] Example 45 is a composition as in any of Examples 42-44, wherein the propylene glycol comprises from about 10wt% to about 40wt% the composition.
[0128] Example 46 is a composition as in any of Examples 42-45, wherein the composition further comprises water, and wherein the water comprises from about 20wt% to about 85wt% the composition.
[0129] Example 47 is a composition as in any of Examples 42-46, wherein the composition comprises an effective amount of the propylene glycol for making the composition water soluble and increasing absorption by the user of the effective amount of the ginger root extract.
[0130] Example 48 is a composition as in any of Examples 42-47, wherein the composition is an aqueous solution configured to administered to the user during an endoscopy procedure by flushing a large intestine of the user with the composition.
[0131] Example 49 is a composition as in any of Examples 42-48, wherein the effective amount of the ginger root extract comprises 6-gingerol and 6-shogaol.
[0132] Example 50 is a composition as in any of Examples 42-49, wherein the composition is water soluble.
[0133] Example 51 is a composition as in any of Examples 42-50, wherein the composition is prepared for oral administration to the user.
[0134] The foregoing description has been presented for purposes of illustration. It is not exhaustive and does not limit the invention to the precise forms or embodiments disclosed. Modifications and adaptations will be apparent to those skilled in the art from consideration of the specification and practice of the disclosed embodiments. For example, components described herein may be removed and other components added without departing from the scope or spirit of the embodiments disclosed herein or the appended claims.
[0135] Other embodiments will be apparent to those skilled in the art from consideration of the specification and practice of the disclosure disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.
Claims
1. A method for increasing visibility of a gastrointestinal tract of a user during an endoscopy procedure, the method comprising: flushing at least a portion of the gastrointestinal tract of the user with a composition during the endoscopy procedure, wherein the composition comprises: an effective amount of ginger root extract for reducing a presence of gas bubbles in the gastrointestinal tract of the user; propylene glycol; and sodium chloride.
2. The method of claim 1, wherein the composition further comprises one or more of citric acid or ascorbic acid.
3. The method of claim 1, wherein the propylene glycol is an effective amount of propylene glycol for making the composition water soluble and increasing absorption by the user of the effective amount of the ginger root extract.
4. The method of claim 1, wherein the effective amount of the ginger root extract comprises from about 3wt% to about 25wt% the composition.
5. The method of claim 1, wherein the propylene glycol comprises from about 10wt% to about 40wt% the composition.
6. The method of claim 1, wherein the composition further comprises water, and wherein the water comprises from about 20wt% to about 85wt% the composition.
7. The method of claim 1, further comprising providing the composition to the user for consumption prior to the endoscopy procedure.
8. The method of claim 1, wherein flushing at least a portion of the gastrointestinal tract of the user comprises injecting the composition into a large intestine of the user via a water channel and/or auxiliary channel of an endoscopic instrument used for performing the endoscopy procedure.
9. The method of claim 1, wherein flushing at least a portion of the gastrointestinal tract of the user comprises directly injecting the composition into a large intestine of the user with a syringe.
10. The method of claim 1, wherein the effective amount of the ginger root extract comprises 6-gingerol and 6-shogaol.
11. The method of claim 1, wherein the composition is water soluble.
12. The method of claim 1, further comprising cleaning an endoscopic device used for performing the endoscopy procedure by washing the endoscopic device with water.
13. The method of claim 1, further comprising cleaning an endoscopic device used for performing the endoscopy procedure by washing the endoscopic device with alcohol.
14. The method of claim 1, further comprising disinfecting an endoscopic device used for performing the endoscopy procedure such that the endoscopic device can be repurposed.
15. A composition comprising: an effective amount of ginger root extract for reducing a presence of gas bubbles in at least a portion of a gastrointestinal tract of a user; propylene glycol; and sodium chloride.
16. The composition of claim 15, further comprising one or more of citric acid, ascorbic acid, sodium chloride, or potassium sorbate.
17. The composition of claim 15, wherein the effective amount of the ginger root extract comprises from about 3wt% to about 25wt% the composition.
18. The composition of claim 15, wherein the propylene glycol comprises from about 10wt% to about 40wt% the composition.
19. The composition of claim 15, wherein the composition further comprises water, and wherein the water comprises from about 20wt% to about 85wt% the composition.
20. The composition of claim 15, wherein the composition comprises an effective amount of the propylene glycol for making the composition water soluble and increasing absorption by the user of the effective amount of the ginger root extract.
21. The composition of claim 15, wherein the composition is an aqueous solution configured to administered to the user during an endoscopy procedure by flushing a large intestine of the user with the composition.
22. The composition of claim 15, wherein the effective amount of the ginger root extract comprises 6- gingerol and 6-shogaol.
23. The composition of claim 15, wherein the composition is water soluble.
24. The composition of claim 15, wherein the composition is prepared for oral administration to the user.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21743702.9A EP4093259A4 (en) | 2020-01-20 | 2021-01-20 | Compositions and methods for improving visibility of the gastrointestinal tract for endoscopy procedures |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/747,108 US11554155B2 (en) | 2020-01-20 | 2020-01-20 | Compositions and methods for improving gastrointestinal function |
US16/747,111 | 2020-01-20 | ||
US16/747,108 | 2020-01-20 | ||
US16/747,111 US11376301B2 (en) | 2020-01-20 | 2020-01-20 | Compositions and methods for improving visibility of the gastrointestinal tract for endoscopy procedures |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021150638A1 true WO2021150638A1 (en) | 2021-07-29 |
Family
ID=76992609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/014231 WO2021150638A1 (en) | 2020-01-20 | 2021-01-20 | Compositions and methods for improving visibility of the gastrointestinal tract for endoscopy procedures |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4093259A4 (en) |
WO (1) | WO2021150638A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11554155B2 (en) | 2020-01-20 | 2023-01-17 | Advanced Health Solutions LLC | Compositions and methods for improving gastrointestinal function |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120053239A1 (en) * | 2006-12-07 | 2012-03-01 | Eli Ehrenpreis | Treatment for intestinal gas, bloating, microscopic colitis, inflammatory bowel disease and traveler's diarrhea using colloidal bismuth subcitrate |
US20120219642A1 (en) * | 2009-10-14 | 2012-08-30 | Gi Innovations, Pllc | Colon cleansing of residual stool and secretions during colonoscopy |
EP3184115A1 (en) * | 2015-12-22 | 2017-06-28 | S.I.I.T. S.r.l.-Servizio Internazionale Imballaggi Termosaldanti | Oral compositions for the treatment of gastroesophageal reflux disease |
US20180104225A1 (en) * | 2013-10-17 | 2018-04-19 | Yoon Sik Kang | Bowel cleansing composition |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008070783A2 (en) * | 2006-12-07 | 2008-06-12 | Herbalscience Singapore Pte. Ltd. | Compositions and methods comprising zingiber species |
BR112013014827A2 (en) * | 2010-12-13 | 2016-10-04 | Antony Wettstein | gastric and colonic formulations and methods for producing and using the same |
KR101549746B1 (en) * | 2013-08-22 | 2015-09-04 | 충북대학교 산학협력단 | Composition comprising solvent fractionated extracts of Zingiber officinale, which are useful for the prevention, improvement and treatment of functional gastrointestinal and motility disorders |
WO2015046532A1 (en) * | 2013-09-30 | 2015-04-02 | ナガセ医薬品株式会社 | Endoscope lens cleaner |
US20200108115A1 (en) * | 2017-03-29 | 2020-04-09 | Benny Antony | Medicinal composition derived from multiple plant sources for gastrointestinal disorder |
-
2021
- 2021-01-20 EP EP21743702.9A patent/EP4093259A4/en active Pending
- 2021-01-20 WO PCT/US2021/014231 patent/WO2021150638A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120053239A1 (en) * | 2006-12-07 | 2012-03-01 | Eli Ehrenpreis | Treatment for intestinal gas, bloating, microscopic colitis, inflammatory bowel disease and traveler's diarrhea using colloidal bismuth subcitrate |
US20120219642A1 (en) * | 2009-10-14 | 2012-08-30 | Gi Innovations, Pllc | Colon cleansing of residual stool and secretions during colonoscopy |
US20180104225A1 (en) * | 2013-10-17 | 2018-04-19 | Yoon Sik Kang | Bowel cleansing composition |
EP3184115A1 (en) * | 2015-12-22 | 2017-06-28 | S.I.I.T. S.r.l.-Servizio Internazionale Imballaggi Termosaldanti | Oral compositions for the treatment of gastroesophageal reflux disease |
Non-Patent Citations (2)
Title |
---|
See also references of EP4093259A4 * |
WEXNER, S.D. FORCE, T. BECK, D.E. BARON, T.H. FANELLI, R.D. HYMAN, N. SHEN, B. WASCO, K.E.: "A consensus document on bowel preparation before colonoscopy: Prepared by a Task Force From The American Society of Colon and Rectal Surgeons (ASCRS), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES)", GASTROINTESTINAL ENDOSCOPY, ELSEVIER, NL, vol. 63, no. 7, 1 June 2006 (2006-06-01), NL, pages 894 - 909, XP005454289, ISSN: 0016-5107, DOI: 10.1016/j.gie.2006.03.918 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11554155B2 (en) | 2020-01-20 | 2023-01-17 | Advanced Health Solutions LLC | Compositions and methods for improving gastrointestinal function |
Also Published As
Publication number | Publication date |
---|---|
EP4093259A4 (en) | 2024-04-10 |
EP4093259A1 (en) | 2022-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shi et al. | Chitosan oligosaccharide-mediated attenuation of LPS-induced inflammation in IPEC-J2 cells is related to the TLR4/NF-κB signaling pathway | |
Wang et al. | Subchronic toxicity study of corn silk with rats | |
Madarati et al. | Preference and usage of intracanal medications during endodontic treatment | |
WO2021150638A1 (en) | Compositions and methods for improving visibility of the gastrointestinal tract for endoscopy procedures | |
Cosentino et al. | Anti-inflammatory effects exerted by Killox®, an innovative formulation of food supplement with curcumin, in urology. | |
US11376301B2 (en) | Compositions and methods for improving visibility of the gastrointestinal tract for endoscopy procedures | |
CN110338284A (en) | A kind of mongolian veterinary drug feed addictive and preparation method and application for preventing and treating sheep urinary calculus | |
Aboubakr et al. | Evaluation of antibacterial effect against E. Feacalis and smear layer removal ability of turmeric extract solution as a root canal irrigant for primary anterior teeth: An in-vitro study | |
CN1686185A (en) | Traditional Chinese medicina preparation for treating oral cavity, throat disease and its preparation method | |
WO2014030250A1 (en) | Antitumor agent | |
JP2798287B2 (en) | Anti-inflammatory agent | |
CN101152546B (en) | Externally used preparations with functions of anti-inflammation, relieving itching and sterilization disinfection, and method for preparing the same | |
US12115206B2 (en) | Compositions and methods for improving gastrointestinal function | |
JP5903280B2 (en) | Intestinal regulating agent, bowel movement improving agent, and constipation improving agent | |
JP2002322079A (en) | Helicobacter pylori degerming composition, antibacterial agent and degerming agent against helicobacter pylori | |
CN106237029B (en) | A kind of aloe antibiotic gel and preparation method thereof | |
CN103110609A (en) | Film coating agent for treating dental ulcer and preparation method thereof | |
Dvivedi et al. | Effect of curcumin on glucose absorption: an experimental study on albino rats | |
Oyewole et al. | Bio-prospecting for fertility in humans: An update on herbal therapy | |
CN106619949A (en) | Veterinary drug with broad-spectrum bactericidal and antiviral effects | |
UM et al. | Phytochemical and Pharmacological Aspects of Cissus quadrangularis in Ayurveda | |
Koda et al. | Effects of horseradish leaf extracts on young mice fed an excessive cholic acid supplemented diet: a preliminary study | |
US8623914B2 (en) | Medical composition | |
AU2008241370B2 (en) | Essential oil of kunzea ambigua and methods of use | |
Saleman et al. | Antihelicobacter pylori activity by powdered of Ginger, Pomegranates, Arabic gum and Curcuma mixed with honey |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21743702 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021743702 Country of ref document: EP Effective date: 20220822 |